A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Leukemias (Ph+CML With T315I Mutation Only).

Trial Profile

A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Leukemias (Ph+CML With T315I Mutation Only).

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Rebastinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 31 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Oct 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 30 Jul 2012 Planned end date changed from 1 Nov 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top